Good Morning Investors!!! Oil is back at the center of the market story this morning after Monday’s relief faded and crude pushed higher again overnight, while Treasury yields also turned back up, keeping pressure on rate-sensitive parts of the market. That leaves investors watching two big questions at once: is this just another short-lived scare, or are higher energy costs and tighter financial conditions starting to slow the economy in a more meaningful way? Today’s early business activity data and tonight’s KB Home results should help answer that, while Gilead’s latest deal offers a reminder that company-specific moves are still very much in play beneath the macro noise.
|
Key Market Drivers
Oil’s relief trade is already wobbling: Travel and other fuel-sensitive groups bounced hard Monday when Brent settled down more than 10%, and Wall Street’s volatility gauge finished at 26.15 after touching 31.04 earlier in the day. That calmer mood started to fray again overnight after Tehran said no talks with Washington had taken place and Israeli officials warned any deal still looked like a long shot. Early Tuesday, Brent was back around $101.19 and West Texas Intermediate (WTI), the main US oil benchmark, was near $90.28. For investors, that means airlines, cruise lines, retailers, and other fuel-sensitive businesses are still trading on headline risk, while energy producers keep the cleaner tailwind. Watch whether the Strait of Hormuz starts moving more normally and whether Brent can stay above $100. 
Gasoline Prices – 1yr Chart – March 24, 2026
The Treasury breather did not last: Bond markets also gave back some of Monday’s relief. Overnight, the 2-year Treasury yield rose as much as 0.085 percentage point to 3.916%, and the 10-year was up about 0.03 point at 4.368%, as traders reversed part of the prior session’s bond rally and moved back toward a more hawkish rate view. That matters because higher yields raise borrowing costs and reduce what investors are willing to pay for future earnings, which can hit smaller companies, homebuilders, and rate-sensitive growth stocks first. The next read comes later this morning with fresh March business-activity data, and again at 6:30 PM ET when Fed Governor Michael Barr is due to speak. Europe’s early data flashed a tougher mix: The March Purchasing Managers’ Index (PMI) (business activity survey) pointed to slower growth and hotter costs across key overseas markets. The euro zone composite reading fell to 50.5 from 51.9, Germany slipped to 51.9 from 53.2, and the UK dropped to 51.0 from 53.7 as firms reported sharper pressure from fuel, transport, and supply disruptions. That is the kind of setup that revives stagflation, which is slow growth paired with sticky inflation. It can hit exporters, industrial firms, travel names, and consumer businesses that depend on healthy overseas demand before it shows up in headline GDP. Asia is already showing strain too, with foreign investors pulling a net $50.45 billion from regional equities this month, so the next tell is whether later US business-activity data start to show the same squeeze. Housing is still one of the clearest stress tests: Monday’s US construction report showed the pressure is not just theoretical. Construction spending fell 0.3% in January versus expectations for a 0.1% rise, residential spending dropped 0.8%, and spending on new single-family homes slipped 0.2%, which is not what strength looks like when borrowing costs are climbing. Mortgage rates have jumped to 6.22% from 5.98% just before the war began, so this is now feeding into real activity as well as market pricing. Higher rates and pricier materials can squeeze builders, lenders, and housing-linked retailers even if the broader market has a better day. Tonight’s housing check comes from KB Home, which reports after the close and holds its earnings call at 5:00 PM ET. |
|
Auto Makers
US automakers are back in focus because the industry is getting squeezed from both sides. New vehicle prices are still high, with the average transaction price (ATP) near $49,000 (according to Kelley Blue Book), while gasoline prices have jumped again. That puts buyers, lenders, and car companies in the same tight corner, and it matters because autos touch consumer spending, credit, steel, chips, and energy all at once.
So far, the showroom has not cracked. GM said fuel prices would likely need to stay high for four to six months before buyers meaningfully shift what they want, which suggests product mix is still doing a lot of the heavy lifting. The fresh angle now is not just demand, but whether affordability, tariffs, and financing costs start leaning on margins at the same time.
General Motors (GM):
GM sells everything from Chevrolet to Cadillac, but its real edge in North America is its mix of full-size pickups and sport utility vehicles, plus a few lower-priced crossovers that keep it from being all steak and no vegetables. That broader lineup gives it more room than some rivals if budget-conscious buyers start pulling back. The timely question is whether that balance holds if fuel stays high, because management said recent gas-price spikes have not yet changed sales behavior while truck inventory has been lean ahead of new launches.
Ford Motor (F):
Ford stands out for its F-Series truck franchise and its deep reach into commercial fleets, which makes it more tied to work-truck demand than many peers. That can be a strength when business spending is healthy, but it also leaves Ford exposed to aluminum costs and tariff noise. In February, Ford projected 2026 earnings before interest and taxes of $8 billion to $10 billion, while warning tariffs could add about $2 billion in costs this year.
Toyota Motor (TM):
Toyota is the global heavyweight here, and its big advantage is scale in hybrids. While some rivals are still trying to guess how fast battery-only demand will grow, Toyota has a middle-lane product that many mainstream buyers already understand. The company raised its full-year operating profit outlook to 3.8 trillion yen in February, and it has also pointed to a longer-term push to lift hybrid and plug-in hybrid output.
InvestorsGrow Takeaway:
For everyday investors, the cleanest macro signal here is the 10-year Treasury yield, because higher long-term rates tend to feed into auto-loan costs and monthly payments. Two smart KPIs to watch are ATP and dealer inventory, often tracked as days’ supply, because together they show whether pricing power is real or just being held up by tight stock. The red flag is simple: if incentives rise while financing stays expensive, margins can get squeezed fast. If rates stay high while days’ supply builds, expect the industry’s profit story to get bumpier.
|
Gilead Sciences (GILD)
Gilead Sciences (GILD) is a large drugmaker best known for HIV medicines, but it also sells treatments for liver disease, cancer, and other serious illnesses. Think of it like a medicine landlord with a few very important tenants, and management is always trying to make sure one rent check does not carry the whole building.
The fresh catalyst is a deal. Gilead said Monday it will buy privately held Ouro Medicines for up to $2.18 billion, including $1.68 billion up front, to add an early-stage immune-disorder drug called OM336; shares were up about 3% in early Tuesday premarket trading after the news.
GILD Forward PE Ratio, 3-24-2026
Stepping back, and the stock context is pretty solid. Gilead is up about 28% over the past year and roughly 130% from early 2021 levels, which tells you the market has become more willing to pay for its newer growth story, not just its old HIV cash flow.
Why the move makes sense is pretty simple: Gilead has been trying to lean less on its core HIV business while COVID drug sales fade and patent cliffs get closer. It is also shopping for growth more aggressively, after agreeing last month to buy partner Arcellx for up to $7.8 billion. In autoimmune disease, it is trying to push into markets long ruled by giants like AbbVie and Johnson & Johnson, and with roughly $29.4 billion of 2025 revenue and a market value near $170 billion, this Ouro deal is a bolt-on, not a cannonball.
One number investors will keep staring at is Gilead’s $20.8 billion in 2025 HIV product sales, including $14.3 billion from Biktarvy alone. That matters because it shows how much of the company’s engine still runs on one therapy area, so every new asset in immunology or oncology is really part science bet, part balance-of-power project inside the business.
The next watch items are straightforward: first-quarter results, the sales ramp for Yeztugo, and any update on the planned Galapagos cost-sharing arrangement around Ouro’s assets. If Yeztugo keeps building and OM336 moves cleanly through development, the diversification story gets easier to believe; if not, investors may decide Gilead is still wearing too much of its old uniform.
InvestorsGrow Takeaway:
What is really going on here is that Gilead is using its balance sheet to buy future growth while it still has strong cash flow from HIV. The upside case is clear enough: newer prevention drugs gain traction, oncology improves, and small acquisitions like this one add fresh shots on goal. The risk is just as clear: OM336 is still early, drug development is expensive, and pipeline deals do not help much if the core business slows faster than the new pieces mature.
